Please ensure Javascript is enabled for purposes of website accessibility

Rockville-based EntreMed cuts loss in first quarter

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing drugs for the treatment of cancer, reduced its net loss in the 2013 first-quarter, reporting a loss of $1.1 million, or 5 cents per diluted share versus a net loss of $2.5 million, or 23 cents per diluted share, for the same period last year.

The company took in no revenue in the first quarter of either year.

EntreMed called the results “in line with our expectations,” noting decreased research and development costs, and lower general and administrative costs.

EntreMed is focused on advancing its lead drug candidate, ENMD-2076, as a treatment for various types of cancer.